American Society of Hematology Annual Meeting

Abecma May Improve Quality of Life in Previously Treated Myeloma

December 10th 2023, 4:00pm

Article

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

Tecartus Induces Responses in Real-World Population of High-Risk R/R MCL

December 10th 2023, 12:25am

Article

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Tecvayli Outcomes Similar in Clinic And Trials for R/R Myeloma

December 9th 2023, 11:06pm

Article

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

All-Oral Regimen Demonstrates Survival Benefits, Safety in AML Subset

December 9th 2023, 8:39pm

Article

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

Novel Drug May Provide New Treatment Option for Pretreated Relapsed-Refractory Lymphoma

December 26th 2022, 2:00pm

Article

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Three-Drug Regimen After Transplant May Improve Relapse-Free Survival in GVHD

December 19th 2022, 2:00pm

Article

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Survival and Treatment Response May Be Further Improved With Brukinsa Versus Imbruvica for CLL/SLL

December 14th 2022, 8:00pm

Article

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.

Calquence Tends to Be a Shorter-Lived Frontline Regimen Than Imbruvica for Leukemia Subtype

December 13th 2022, 10:00pm

Article

Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022, 5:00pm

Article

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

CAR-T Cell Therapy Continues to Impress in Myeloma Treatment

December 15th 2021, 7:00pm

Article

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.